Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Neoplasms 3Multiple Myeloma 2Desmoid Tumors 2Paraproteinemias 1Neoplasms, Plasma Cell 1Hematologic Diseases 1Corneal Diseases 1Breast Neoplasms 1Blood Protein Disorders 1

Interventions

Dexamethasone 7Lenalidomide 5isatuximab 3fludarabine 3daratumumab 3Cyclophosphamide 3Bortezomib 3pomalidomide 2Tacrolimus 2Alemtuzumab 2plerixafor 1ofatumumab 1nirogacestat 1fludarabine phosphate 1Whole-Body Irradiation 1Tissue Banks 1Thalidomide 1Stem Cell Transplantation 1Rifaximin 1Ranitidine 1Mycophenolic Acid 1Melphalan 1Granulocyte Colony-Stimulating Factor 1Etoposide 1Doxorubicin 1Diphenhydramine 1Clonal Hematopoiesis 1Cisplatin 1Chromatin Immunoprecipitation Sequencing 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Paraproteinemias × nirogacestat × Clear all
NCT05573802 2023-10-24

A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma

Hellenic Society of Hematology

Phase 1/2 Recruiting
36 enrolled
Plasma cell

Blood Protein Disorders, Corneal Diseases, Hematologic Diseases, Multiple Myeloma, Neoplasms, Paraproteinemias, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡